BLTE (Belite Bio) Price-to-Tangible-Book : 13.71 (As of May. 09, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Price-to-Tangible-Book?

As of today (2025-05-09), Belite Bio's share price is $61.10. Belite Bio's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $4.46. Hence, Belite Bio's Price to Tangible Book Ratio of today is 13.71.

The historical rank and industry rank for Belite Bio's Price-to-Tangible-Book or its related term are showing as below:

BLTE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 13.7 Med: 15.31 Max: 18.09
Current: 13.7

During the past 5 years, Belite Bio's highest Price to Tangible Book Ratio was 18.09. The lowest was 13.70. And the median was 15.31.

BLTE's Price-to-Tangible-Book is ranked worse than
89.93% of 1201 companies
in the Biotechnology industry
Industry Median: 2.58 vs BLTE: 13.70

A closely related ratio is called PB Ratio. As of today, Belite Bio's share price is $61.10. Belite Bio's Book Value per Sharefor the quarter that ended in Dec. 2024 was $4.58. Hence, Belite Bio's P/B Ratio of today is 13.33.

Belite Bio Price-to-Tangible-Book Historical Data

The historical data trend for Belite Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Price-to-Tangible-Book Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

18.09

15.31

14.16

Belite Bio Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial									15.31	11.85	12.20	12.90	14.16

Competitive Comparison of Belite Bio's Price-to-Tangible-Book

For the Biotechnology subindustry, Belite Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Belite Bio's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Belite Bio Price-to-Tangible-Book Calculation

Belite Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	61.10	/	4.456
	=	13.71

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Belite Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Belite Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

D01:Germany

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.